PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT
Bleeding, Thrombosis and Vascular Biology · 26.10.2026 · 5 (s3)
DOI: 10.4081/btvb.2026.943 ↗Kurz gefasst
Fallbericht in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 26.10.2026. Verfasst von Ilaria Nichele. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background. A small proportion of patients with mild haemophilia A develop factor VIII inhibitors, which can convert a mild disorder into a severe spontaneous bleeding. Intensive perioperative use of factor VIII and some specific mutations induce a particularly high risk for inhibitor development, but risk factors are incompletely understood. Management aims to control the bleeding mainly with by-passing agents and to eradicate the inhibitor when the spontaneous clereance doesn’t occur. Emicizumab provides effective prophylaxis in difficult-to-treat mild haemophilia A patients with inhibitor. However, bypassing agents, preferably recombinant activated factor FVII, are required for effective bleed management. No serious adverse events have been described so far with the use of recombinant activated factor VII. Case Report. A 54-years old man affected with mild haemophilia (FVIII level 7%) was referred to our hospital from another center for a prothesic knee surgery due to advance haemohilic artropaty on October 2025. On demand therapy with plasmatic FVIII was maintained until the surgery with very few infusion over the years and no history of inhibitor. The surgery was managed with blous of FVIII immediately before, then with continuous infusion for the first four days and again boulus of plasmatic FVIII for three weeks included rehabilitation period. No inhibitor was detected at discharge from the hospital. After one month, spontaneous muscle haematoma of left thigh happened and the coagulation check showed severe decrease of FVIII (
Zitieren
APA
Nichele, I. (2026). PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT. Bleeding, Thrombosis and Vascular Biology, 5(s3). https://doi.org/10.4081/btvb.2026.943
Vancouver
Nichele I. PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT. Bleeding, Thrombosis and Vascular Biology. 2026;5(s3). doi:10.4081/btvb.2026.943
BibTeX
@article{Nichele2026,
author = {Nichele, Ilaria},
title = {PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
volume = {5},
number = {s3},
doi = {10.4081/btvb.2026.943}
}
EUVIMED